Navigation Links
Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
Date:12/1/2009

ROCKVILLE, Md., Dec. 1 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that the waiting period has expired under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 with respect to Vanda's agreement, dated October 12, 2009, with Novartis Pharma AG, and that the agreement is now effective. Expiration of the waiting period, and the resulting effectiveness of the agreement, triggers an upfront payment to Vanda of $200 million.

Pursuant to the agreement, Novartis will have exclusive commercialization rights to Fanapt(TM) in the U.S. and Canada. Novartis will be responsible for the further clinical development activities in these territories, including the development and commercialization of a long-acting injectable (or depot) formulation of Fanapt(TM). Vanda will retain rights to commercialize Fanapt(TM) oral and depot formulations outside the U.S. and Canada, but Novartis has the option to enter into discussions with Vanda to co-commercialize Fanapt(TM) or receive sales royalties outside the U.S. and Canada.

About Vanda

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders. For more on Vanda, please visit http://www.vandapharma.com.

SOURCE Vanda Pharmaceuticals Inc.


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
4. Vanda Presents Phase III Iloperidone Efficacy Data
5. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
6. Vanda Pharmaceuticals Provides Update on Iloperidone
7. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
8. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
9. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... JACKSON, Mich. , May 31, 2016 /PRNewswire/ ... a market-leading provider of anesthesia information management systems ... Doug Marcey as Vice President of ... establish and lead all aspects of the company,s ... and Plexus TG customers to determine the expansion ...
(Date:5/31/2016)... May 31, 2016 Aloe vera ... food, cosmetics and pharmaceuticals, with global volume to surpass ... 1.6 Bn. Demand for aloe vera extracts ... yogurts will continue its upward momentum in 2016 as ... boost positive sentiment on aloe vera, with wide-ranging applications ...
(Date:5/31/2016)... NESS ZIONA, Israel , ... a regenerative medicine company utilizing its proprietary plant-based rhCollagen ... has received authorization from the Chief Scientist of ... approximately 50% of its NIS 12 million development project ... million, measurably higher than last year,s authorized grant, which ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... ... device that enables unprecedented portability and convenience. , The Cube is exceptionally small—it ... in size, the Cube fits easily into any space, whether in a hospital, ...
(Date:5/31/2016)... , ... May 31, 2016 , ... The Global ... today released ten predictions on the future of wellness, travel, spa and beauty in ... travel, spa and beauty companies to leading economists and researchers - to forecast where ...
(Date:5/31/2016)... ... ... The Orthopaedic Research and Education Foundation (OREF) is pleased to announce the following ... term as president in March, succeeding John J. Callaghan, MD, who remains on the ... Kyle, MD, will serve as chair, corporate development, succeeding Thomas P. Schmalzried, MD, in ...
(Date:5/31/2016)... ... May 31, 2016 , ... In a recent interview on The Greenburgh ... New Rochelle, NY-based WVOX (1460 AM), leading medical insurance advocate Adria Goldman ... country’s “modern medical money maelstrom.” , During the interview with Mr. Feiner that ...
(Date:5/31/2016)... ... May 31, 2016 , ... To ... solutions to the healthcare industry, The University of Scranton is adding a Certificate ... path to a career in rapidly growing field of healthcare information. , ...
Breaking Medicine News(10 mins):